Theresia Akhlaghi retweetledi
QME
Theresia Akhlaghi
166 posts
Theresia Akhlaghi
@TAkhlagh
Hematology and Oncology fellow @WeillCornell. IM @msm_msw @IcahnMountSinai, NYC. MD @lunduniversity, Sweden.
New York, NY Katılım Mart 2014
475 Takip Edilen330 Takipçiler
Theresia Akhlaghi retweetledi
🧵 1/6 Now online @BloodPortfolio: Time to revise/re-evaluate #Myeloma Diagnostic Criteria? @ManniMD1 and I make an argument that sFLC ratio≥100 should not be used as a standalone criterion due to the risk of systematic overdiagnosis and overtreatment!
(Figure below shows that this is a heterogeneous group with a vast majority having a low risk of progression to CRAB MM)
tinyurl.com/3yytwmn9
English
Thrilled to be @Myeloma_Doc paper of the day! In our modern SMM cohort, we found more moderate progression risk than historically reported, even in 2/20/20 high-risk. Aligns with @thanosdimop & @rajshekharucms. Excited for what @sykristinsson & @SigrunThorstei1 find in iStopMM!
Robert Z. Orlowski@Myeloma_Doc
#Myeloma Paper of the Day: Smoldering myeloma pts from MSKCC were 49% low risk, 30.5% intermediate, 20.5% high by 2/20/20; 1/2/5/10-yr progression rates 1.3/4.8/12.2/28.9%, 7.6/12.1/34.1/40.4% & 16/34.8/66.7/83.2% for low, intermediate & high risk: pubmed.ncbi.nlm.nih.gov/41380108/. #mmsm
English
English
Theresia Akhlaghi retweetledi
Important findings from @MSKCancerCenter in @BloodPortfolio on progression rates in contemporary smoldering myeloma (~80% had baseline whole-body MRI or PET/CT imaging)
Key findings that impact clinical practice:
✅Annual progression risk to CRAB is now ~5% (first 5 years), down from the historically quoted 10%!
✅Even with SLiM-CRAB criteria, progression risk remains ~6.8% annually (first 5 years)
✅20/2/20 high-risk SMM patients:
2-year progression to SLiM-CRAB: ~35%
2-year progression to CRAB: ~27%
Previously quoted risk was ~50%
✅At median 7-year follow-up, overall survival was similar across 20/2/20 risk groups
These data provide valuable evidence for shared decision-making when counseling high-risk SMM patients on active surveillance vs. early treatment.
@MalinHultcrantz @TAkhlagh
@Daw6Jessie
tinyurl.com/bdkdvrzx
English
Stop by PF1896 during the poster session tomorrow to learn about risk stratification of Asymptomatic Waldenström Macroglobulinemia! @MarkBustoros @WCMHemOncFellow @WCMMyelomaCtr @WeillCornell
English
With Drs Dreyling,Sonneveld,Terpos and Gavriatopoulou today at EHA 2025 after the presentation of the new EHA EMN guidelines for the treatment of multiple myeloma The room was packed!!!
English
@TAkhlagh please stop by our filming location across from Coral 4. I would love to say hello.
English
Theresia Akhlaghi retweetledi
#mmsm #IMWG25 @NEJM
Nice figure @FrancescoMaura4 indicating that there is a group of SMM who has immune containment brake system that prevent progression into MM where early intervention may not be appropriate
English
Theresia Akhlaghi retweetledi
It was a great experience and honor to present during my 1st IMWG in my hometown Milan 🇮🇹 our new data on MGUS/SMM progression #mmsm #wgs
Joshua Richter, MD, FACP@JoshuaRichterMD
We’re off to an amazing start with @FrancescoMaura4 walking us through the nuts and bolts of progression from MGUS to myeloma along with @VincentRK @mvmateos @IrenemGhobrial @thanosdimop. @IMFmyeloma #mmsm
English
@RubenNiesvizky @christinemphmd @MarkBustoros @ASCO Thank you so much for your support and kind words! Following in the footsteps of the incredible people I get to learn from every day! 🙏🏽
English
So grateful to be supported by an exceptional program director @christinemphmd and my dedicated mentors @MarkBustoros and @RubenNiesvizky! Excited to celebrate with everyone at @ASCO this week!
Christine A. Garcia, MD, MPH@christinemphmd
Congratulations to Dr. Theresia Akhlaghi (@TAkhlagh) on her @ASCO @ConquerCancerFd Young Investigator Award and to her mentor, Dr. Mark Bustoros (@MarkBustoros)! Looking forward to celebrating this week!
English
Theresia Akhlaghi retweetledi
Our fellowship program director @christinemphmd is sharing her knowledge about oncology training and fellowships during a special session at #ASCO25 this morning. Stop by the trainee & early career lounge to listen in!
GIF
English
Great work presented by @FaltasLab from @WCMDeptofMed
Tom Powles@tompowles1
CLONEVO: Preoperative abemaciclib (CDK4/6 inhibitor) in cisplatin ineligible MIBC(n=20) pCR= 18% seems modest. RB1 phosphorylation confirmed on-target activity. Serial ctDNA showed 27% ⬇️ in TF. Great biomarker work showing suppression of E2F-dependent cell proliferation #ASCO25
English
English
Thank you so much for your support @MyelomaTeacher! Hopefully we can celebrate together at #EHA2025!
@MyelomaTeacher - Cindy Chmielewski@MyelomaTeacher
Congratulations to these two Young #Myeloma Investigators for receiving a @ConquerCancerFd YIA at #ASCO25. Being the patient advocate on their applications, I can attest their research projects are outstanding! @Zach_Avigan @TAkhlagh @WeillCornell @TischCancer #mmsm
English
There’s one more hour left to stop by @Jonathanwlee23 poster to learn about PALB2-mutated PDAC!
English
Theresia Akhlaghi retweetledi
Thrilled that Dr. Saad Usmani @szusmani Chair of the myeloma program @MSKCancerCenter will receive the Giants of Cancer Care Award for Myeloma @OncLive tomorrow. #ASCO25
Congrats dear friend! Best wishes on behalf of all our myeloma colleagues. Cheers!
English
Theresia Akhlaghi retweetledi
Very proud of our 2nd @WCMHemOncFellow, Dr. Theresia Akhlaghi (@TAkhlagh) on her @ASCO @ConquerCancerFd Young Investigator Award! Congrats to all awardees!
@WCM_MeyerCancer
@nyphospital
@WCMDeptofMed
English
Congrats @TAkhlagh 👏🏼👏🏼👏🏼
@MyelomaTeacher - Cindy Chmielewski@MyelomaTeacher
Congratulations to these two Young #Myeloma Investigators for receiving a @ConquerCancerFd YIA at #ASCO25. Being the patient advocate on their applications, I can attest their research projects are outstanding! @Zach_Avigan @TAkhlagh @WeillCornell @TischCancer #mmsm
English